Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 9/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 9/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12427249 | 0.85 | PTGS1 (0.55) | PTGS1HDAC1HDAC3HDAC2MAPK1 | |
| SCHEMBL8910665 | 0.85 | PTGS1 (0.55) | PTGS1HDAC1HDAC3HDAC2MAPK1 | |
| SCHEMBL8909870 | 0.85 | PTGS1 (0.55) | PTGS1HDAC1HDAC3HDAC2MAPK1 | |
| SCHEMBL1064630 | 0.83 | HDAC1 (0.74) | PTGS1HDAC1HDAC3HDAC2MAPK1 | |
| SCHEMBL1576313 | 0.82 | PDK1 (0.67) | JAK2TP53MAPTHTTKLK7 | |
| SCHEMBL11394941 | 0.82 | PTGS1 (0.53) | PTGS1HDAC1HDAC3HDAC2MAPK1 | |
| SCHEMBL15711989 | 0.81 | HDAC1 (0.55) | PTGS1HDAC1HDAC3HDAC2MAPK1 | |
| SCHEMBL2733296 | 0.81 | CETP (0.61) | PTGS1HDAC1HDAC3HDAC2MAPK1 | |
| SCHEMBL20051277 | 0.80 | HDAC1 (0.51) | PTGS1HDAC1HDAC6HDAC7HDAC8 | |
| Trifluoroacetic Acid SCHEMBL3600531 | 0.79 | HDAC1 (0.54) | PTGS1HDAC1HDAC3HDAC2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550510-B2 | Solid phase synthesis of arylretinamides | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-20040102650-A1 | Solid phase synthesis of arylretinamides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-05-27 | — | — | US | disclosed |
| US-6696606-B2 | REACTING HEXACHLOROACETONE WITH TRIPHENYLPHOSPHINE; CHLORINATION OF RETINOIC ACID; THEN AROMATIC AMINE; ANTICANCER AGENTS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2004-02-24 | — | — | US | disclosed |
| CN-1118459-C | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha1 adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2003-08-20 | — | — | CN | disclosed |
| US-20030105164-A1 | Solid phase synthesis of arylretinamides | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-06-05 | — | — | US | disclosed |
| WO-2003003987-A2 | SOLID PHASE SYNTHESIS OF ARYLRETINAMIDES | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2003-01-16 | — | — | WO | disclosed |
| EP-0748800-B1 | Pyrimidinedione, pyrimidinetrione, triazinedione derivatives as alpha-1-adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2001-05-09 | — | — | EP | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5688795-A | URINARY TRACTS OBSTRUCTION | SYNTEX (U.S.A.) INC. (US) | 1997-11-18 | — | — | US | disclosed |
| CN-1149051-A | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha1 adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 1997-05-07 | — | — | CN | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
| CN-1136039-A | [3- (4-phenylpiperazin-1-yl) propylamino, thio and oxy ] -pyridine, pyrimidine and benzene derivatives | HOFFMANN LA ROCHE (CH) | 1996-11-20 | — | — | CN | disclosed |
| EP-0711757-A1 | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists | F. Hoffmann-La Roche AG (CH) | 1996-05-15 | — | — | EP | disclosed |
| EP-0580763-A1 | COMPOSITIONS AND METHODS FOR ENDOTHELIAL BINDING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1994-02-02 | — | — | EP | disclosed |
| WO-1992018610-A2 | COMPOSITIONS AND METHODS FOR ENDOTHELIAL BINDING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102650-A1 | Solid phase synthesis of arylretinamides | RARA, LRAT, NR2E3 | PTGS1 3738/4885HDAC1 448/4885HDAC3 266/4885 |
| US-20030105164-A1 | Solid phase synthesis of arylretinamides | RARA, LRAT, NR2E3 | PTGS1 3738/4885HDAC1 448/4885HDAC3 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.